DIAGNODE-2 results and meta-analysis with Diamyd® to be presented at diabetes conference

Results from the phase IIb trial DIAGNODE-2 with intralymphatic administration of Diamyd® as well as the large-scale meta-analysis comprising data from more than 600 individuals treated with Diamyd® showing significant treatment effect in individuals carrying the HLA DR3-DQ2 haplotype, will be presented as oral abstracts by Professor Johnny Ludvigsson and PhD Ulf Hannelius, CEO of Diamyd Medical at the Scandinavian Society of the Science in Diabetes (SSSD) on March 11, 2021.

The abstracts will be presented during the conference session “Diabetes classification and precision medicine”.

The DIAGNODE-2 results, first announced in September 2020, will be presented under the title “Intralymphatic glutamic acid decarboxylase in recent onset Type 1 diabetes: a double-blind randomized placebo-controlled Phase IIb trial (DIAGNODE-2)” by Johnny Ludvigsson, coorindating investigator of DIAGNODE-2 and Professor at Linköping University.

The large-scale meta-analysis, first announced in December 2019, and updated with DIAGNODE-2 results in January 2021, will be presented under the title “Precision Medicine for Type 1 Diabetes - The Influence of HLA, Dose and Administration Route on the Effect of GAD-specific Immunotherapy” by Ulf Hannelius, CEO of Diamyd Medical.

The SSSD meeting will this year be conducted as a virtual meeting on March 11 and 12. Participation in the meeting is free and the program and registration details can be found on https://www.scandinaviandiabetes.org/sssd2021.

About Diamyd Medical
Diamyd Medical develops therapies for type 1 diabetes. The diabetes vaccine Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a genetically predefined patient group in a large-scale meta-analysis as well as in the Company’s European Phase IIb trial DIAGNODE-2, where the diabetes vaccine was administered directly into a lymph node in children and young adults with recently diagnosed type 1 diabetes. A new facility for vaccine manufacturing is being set up in Umeå for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd®. Diamyd Medical also develops the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. An investigator-initiated Remygen® trial in patients living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB.

Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser; phone: +46 8-528 00 399, e-mail: info@fnca.se

For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: ulf.hannelius@diamyd.com

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
info@diamyd.com Reg. no.: 556242-3797 Website: https://www.diamyd.com

The information was submitted for publication, through the agency of the contact person set out above, at 11:45 CET on February 26,  2021.


  PDF version